Literature DB >> 8501569

Serial measurements of neuropeptide Y in plasma for monitoring neuroblastoma in children.

W Rascher1, B Kremens, S Wagner, F Feth, D H Hunneman, R E Lang.   

Abstract

Neuropeptide Y (NPY) was studied as a marker for neuroblastoma in 12 children. All but one patient with neuroblastoma had elevated plasma NPY concentrations at diagnosis. During treatment NPY values returned to normal in 9 of 12 children. All three children without normalization of plasma NPY values died; two of them had a relapse and the third died of toxic effects. Plasma NPY appears to be a sensitive marker of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501569     DOI: 10.1016/s0022-3476(09)90018-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.

Authors:  Susana Galli; Arlene Naranjo; Collin Van Ryn; Jason U Tilan; Emily Trinh; Chao Yang; Jessica Tsuei; Sung-Hyeok Hong; Hongkun Wang; Ewa Izycka-Swieszewska; Yi-Chien Lee; Olga C Rodriguez; Chris Albanese; Joanna Kitlinska
Journal:  Am J Pathol       Date:  2016-10-12       Impact factor: 4.307

Review 2.  Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology.

Authors:  Jason Tilan; Joanna Kitlinska
Journal:  Neuropeptides       Date:  2015-10-26       Impact factor: 3.286

3.  Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance.

Authors:  Yi Ding; MinJae Lee; Yan Gao; Ping Bu; Christian Coarfa; Brian Miles; Arun Sreekumar; Chad J Creighton; Gustavo Ayala
Journal:  Prostate       Date:  2020-10-06       Impact factor: 4.012

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.